1. Monash Health
  2. Monash Health research
  3. Articles
Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/38275
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHawkes E.A.en
dc.contributor.authorOpat S.en
dc.date.accessioned2021-05-14T13:03:00Zen
dc.date.available2021-05-14T13:03:00Zen
dc.date.copyright2017en
dc.date.created20180109en
dc.date.issued2018-01-09en
dc.identifier.citationJournal of Clinical Oncology. 35 (36) (pp 4093-4094), 2017. Date of Publication: 20 Dec 2017.en
dc.identifier.issn0732-183Xen
dc.identifier.urihttps://repository.monashhealth.org/monashhealthjspui/handle/1/38275en
dc.languageenen
dc.publisherAmerican Society of Clinical Oncology (E-mail: jcoservice@asco.org)en
dc.relation.ispartofJournal of Clinical Oncologyen
dc.titleChemoimmunotherapy may not be dead yet in chronic lymphocytic leukemia, but fludarabine plus cyclophosphamide plus rituximab is potentially facing life support.en
dc.typeLetteren
dc.type.studyortrialOpinion, perspective or news-
dc.identifier.doihttp://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1200/JCO.2017.75.4721en
dc.publisher.placeUnited Statesen
dc.identifier.pubmedid29099632 [http://www.ncbi.nlm.nih.gov/pubmed/?term=29099632]en
dc.identifier.source619942571en
dc.identifier.institution(Opat) Monash Health, Clayton, Australia (Opat, Hawkes) Monash University, Melbourne, Australia (Hawkes) Austin Health, Heidelberg, Australia (Hawkes) Eastern Health, Box Hill, Australiaen
dc.description.publicationstatusEmbaseen
dc.rights.statementCopyright 2019 Elsevier B.V., All rights reserved.en
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.openairetypeLetter-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
crisitem.author.deptHaematology-
Appears in Collections:Articles
Show simple item record

Page view(s)

14
checked on Sep 14, 2024

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.